Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Genitourinary 4CNS 4Gastrointestinal 3Thoracic 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Pituitary Neoplasms 1Pituitary Diseases 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sodium Chloride × Endocrine × Clear all
NCT02549768 2016-10-12

Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

Pontificia Universidad Catolica de Chile

Phase 4 Unknown
40 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡